U.S. MarketsSeptember 8 at 09:03 AM

Amgen (AMGN) announces positive phase 3 DeLLphi-305 study, which met its primary endpoint when IMDELLTRA in combination with AstraZeneca's (AZN LN) Imfinzi

StockNow breaking-news AI analysis

Amgen announced that the Phase 3 DeLLphi-305 study met its primary endpoint evaluating IMDELLTRA in combination with AstraZeneca's Imfinzi in extensive-stage small cell lung cancer.

2 stocks

AMGNAmgen Inc$401.82Current price

AZNAstraZeneca PLC$162.31Current price

What do investors think?

Curious what other investors think?Log in to see reactions and join the conversation.

StockNow uses AI to translate and analyze information and does not guarantee its accuracy or completeness.

Amgen (AMGN) announces positive phase 3 DeLLphi-305 study, which met its primary endpoint when IMDELLTRA in combination with AstraZeneca's (AZN LN) Imfinzi

What do investors think?

Today's market highlights

Qatar's Foreign Ministry says they are working with its regional partners and China to resume talks with the US and Iran

AstraZeneca (AZN LN) says Phase III tozorakimab data in COPD showed a 29%-34% reduction in exacerbations

Qualcomm (QCOM) announces a multi-generational pact with Amazon (AMZN) to build next-gen AI data centre infrastructure

Amgen (AMGN) announces positive phase 3 DeLLphi-305 study, which met its primary endpoint when IMDELLTRA in combination with AstraZeneca's (AZN LN) Imfinzi

Related stocks

What do investors think?

Today's market highlights

Qatar's Foreign Ministry says they are working with its regional partners and China to resume talks with the US and Iran

AstraZeneca (AZN LN) says Phase III tozorakimab data in COPD showed a 29%-34% reduction in exacerbations

Qualcomm (QCOM) announces a multi-generational pact with Amazon (AMZN) to build next-gen AI data centre infrastructure